Sonoma Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) is a global healthcare leader specializing in the development and production of stabilized hypochlorous acid (HOCl) products. Operating under patented Microcyn® technology, the company's clinical solutions target a wide range of applications including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health, and non-toxic surface disinfectants. Sonoma sells its products directly or through strategic distribution partnerships in over 55 countries worldwide. The company's corporate headquarters are located in Boulder, Colorado, with primary manufacturing operations in Jalisco, Mexico, and European sales and marketing based in Roermond, Netherlands.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning core HOCl-based products (Microcyn technology) from prescription-heavy to over-the-counter (OTC) consumer markets, leveraging partnerships to launch products like diaper rash and burn relief hydrogels in major U.S. retailers including CVS and Walmart.
Expected impact: Aims to build a broader, more stable revenue base and reduce reliance on irregular institutional orders.
Advancing regulatory initiatives globally, including transitioning all commercialized products in Europe to the new EU Medical Device Regulation (MDR) ahead of the 2028 deadline, and securing Class IIb medical device approval in Ukraine.
Expected impact: Ensures uninterrupted market access in the EU and UK, providing a competitive advantage over smaller peers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Establishes a multi-year supply relationship with a prominent consumer health company to manufacture and supply Microcyn technology-based products.
Terms: Effective October 24, 2025 through March 2027, with potential extensions. Includes obligations to pass cost savings to Kenvue after Sonoma recovers capital investments.
Enables the sale and distribution of Microcyn technology-based products to large retailers in the United States, placing Sonoma's technology into established consumer brands like Bactine.
Terms: Effective January 29, 2025 with an initial term of two years and options for three one-year automatic renewals. Expanded in March, June, and July 2025 to include additional consumer-focused products.
Combines Sonoma's HOCl-based product development expertise with Medline's extensive hospital and healthcare distribution network in the U.S. and Canada.
Terms: Initiated in August 2024, expanded in October 2024, and resulted in the launch of a new co-developed HOCl wound cleanser in October 2025.